(A) Schematic timeline for the bNAb (top) and ART (bottom) experiments.

(B) Plasma viremia for untreated mice. The x axis is days post HIV-1 challenge. The y axis is viral RNA copies/ml. Gray shading indicates values beneath the detection limit of 800 copies/ml. The blue line indicates the geometric mean of plasma viremia.

(C) Plasma viremia for ART-treated mice. Graph as in (B). The blue shading indicates the treatment period with ART.

(D) Plasma viremia for antibody-treated mice. The red arrows indicate antibody tri-mix injections. The dashed red line shows average plasma antibody concentration (μg/ml) for all mice in the group.

(E) Graph as in (D) for mice treated with antibody starting 8 days after HIV-1 challenge.

(F) The proportion of mice that were aviremic at the terminal point for each treatment group (∗p < 0.05; Fisher’s exact test).

(G) Percentage of CD4+ T cells in the spleen at the terminal point measured by flow cytometry, organized by treatment group. A, aviremic; V, viremic.

(H) Cell-associated HIV-1 RNA measured in spleen T cells at the terminal point, plotted as the ratio of HIV-1 RNA to CCR5 copies for each mouse. Gray shading indicates the detection limit of 1.25 × 10−5 copies per cell.

(I) Cell-associated HIV-1 DNA measured in spleen T cells at the terminal point, plotted as the ratio of HIV-1 DNA to CCR5 copies for each mouse. Gray shading indicates the detection limit of 2.0 × 10−5 copies per cell.